Cigna · Vutrisiran ATTR Cm · US health-plan appeal rights

Vutrisiran ATTR Cm denied for missing prior authorization by Cigna?

Q: How long do I have to appeal a Cigna Vutrisiran ATTR Cm denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

If the original prescription wasn't run through prior auth, the path is to submit a PA now with a medical-necessity letter — many plans then back-date approval to the date of service.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Cigna typically requires

Cigna's specific coverage criteria for vutrisiran attr cm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Cigna Amvuttra (Vutrisiran) for ATTR-CM

The Cigna angle on Vutrisiran ATTR Cm

## Why Cigna Requires Prior Authorization for Vutrisiran (ATTR-CM) — and What to Do

Vutrisiran (Amvuttra) is FDA-approved for transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM). Cigna requires prior authorization (PA) for vutrisiran, meaning the prescriber must obtain approval before the drug is dispensed or reimbursed. A prior-authorization denial — or a denial for failure to obtain prior authorization — is a separate process from a clinical denial, and the appeal pathway differs depending on which type you received.

## Why This Denial Is Appealable

If you received a prior-authorization denial (meaning a PA was submitted and rejected), you have the right under ACA §2719 to a full internal appeal and then independent external review. Under ERISA §503 (for employer-sponsored plans), a full-and-fair review is required. The external-review window is typically available for approximately four months after a final internal denial. Expedited review (often resolved within 72 hours) is available when delay would seriously jeopardize your health — a strong argument for ATTR-CM, a progressive and life-threatening condition.

If vutrisiran was dispensed without prior authorization and the claim was denied on that basis, contact your prescriber immediately to submit a retroactive PA, as most plans allow a retroactive authorization process.

## What to Gather for the PA Submission or Appeal

Diagnosis confirmation: Technetium nuclear imaging or cardiac biopsy results, genetic testing (if hereditary), and cardiologist notes confirming ATTR-CM diagnosis and subtype.
Functional severity documentation: Recent cardiology notes documenting disease progression and functional impact.
FDA prescribing label: Obtain the current full prescribing information for vutrisiran from the FDA website and attach it to confirm the approved indication.
Prescriber medical-necessity letter: A letter from your cardiologist that (a) confirms the ATTR-CM diagnosis, (b) states the clinical basis for prescribing vutrisiran, (c) references the FDA-approved indication, and (d) cites applicable ACC/AHA guidance.
Cigna PA criteria: Request Cigna's written prior-authorization criteria for vutrisiran so your submission or appeal addresses each requirement explicitly.

## Criteria-Mapping Structure

For each PA criterion Cigna lists, provide a direct evidentiary response:

> Cigna PA criterion: [paste verbatim] > Supporting documentation: [exact test result, date, or physician note from your chart]

## Timeline

PA appeals generally follow a shorter internal timeline than standard appeals — confirm the exact deadline in your denial letter. If your condition is urgent, request expedited review in writing. After a final internal denial, file for independent external review promptly to preserve your rights within the approximately four-month window.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Cigna appeals

Other denial reasons for Cigna Vutrisiran ATTR Cm

denied as not medically necessary denied for failing step therapy denied as non-formulary denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.